REDEFINE is an ongoing phase 3 trial acting as market evaluation for both CagriSema and cagrilintide, with 60% randomised to CagriSema, 10% cagrilintide, 10% semaglutide, and 20% placebo, where minimum age at inclusion was 55 years with no upper limit [117]
In contrast, no benefits on the rate of decline in glomerular filtration rate have been seen in trials of DPP-4 inhibitors, perhaps because the renal actions of DPP-4 inhibitors are primarily mediated by potentiation of SDF-1, not GLP-1
Battery backup for GLP-1 storage is particularly valuable in areas experiencing grid instability, severe weather events, or planned power shutoffs
Begin increasing sodium and electrolyte intake to pre-adaptation levels
Understanding the Financial Impact of GLP-1s GLP1 medications carry high, persistent costs and are designed for longterm use, making them some of the most expensive chronic drugs on a plan